Last reviewed · How we verify

NCT03568292

Virtual Reality in Reducing Pain and Anxiety in Cancer Participants Undergoing Painful Procedures

Suspended NA Last updated 17 November 2025
What this trial tests

NA trial testing Best Practice in Malignant Neoplasm in 60 participants. Suspended.

Timeline
1 March 2022
Primary endpoint
1 March 2026
1 March 2027

Quick facts

Lead sponsorUniversity of Southern California
PhaseNA
StatusSuspended
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment60
Start date1 March 2022
Primary completion1 March 2026
Estimated completion1 March 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Southern California

Who can join

Adults 18 to 70, any sex, with Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies how well virtual reality (VR) works in reducing pain and anxiety in cancer participants undergoing bone marrow biopsy or lumbar puncture. Virtual reality may impact pain and anxiety during and after the procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Best Practice

Trials testing the same drug.

Other recruiting trials for Malignant Neoplasm

Currently open trials in the same condition.

Other University of Southern California trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03568292.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing